Literature DB >> 17661206

Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.

Selahattin Turen1, Enis Ozyar, Kadri Altundag, Ibrahim Gullu, Ibtisam L Atahan.   

Abstract

We investigated the treatment results and probable prognostic factors in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with neoadjuvant chemotherapy (NCT) plus conventional radiotherapy (RT) or concomitant chemoradiotherapy (CCRT) at our hospital. We retrospectively evaluated 61 patients (48 males, 13 females) with locoregionally advanced NPC treated either with 2 cycles of NCT plus RT (Group A, 37 patients) or with three cycles of NCT plus CCRT (Group B, 24 patients) between September 1995 and October 2002. According to the AJCC 1997 classification system, 19 patients had Stage III disease and 42 had Stage IV. NCT consisted of cisplatin and 5-fluorouracil. Total RT doses were ranged between 59.4-71.6 Gy (median: 66.2 Gy). Concomitant cisplatin (75 mg/m(2)) was given on first days of Weeks 1, 4, 7 of CCRT. Patient sex, histopathologic subtype, T status, ECOG performance status, stage, serum lactate dehydrogenase (LDH) level, and cranial nerve involvement at diagnosis were comparable in the 2 groups. There were statistically significant differences between median follow-up times and N status for the 2 groups. Fifty-five (90.2 percent) patients completed all planned NCT. Univariate analysis revealed the pretreatment LDH level as the only statistically significant prognostic factor for disease-free survival (DFS) and overall survival (OS). Four-year DFS rates were 55.9 percent and 21.3 percent for patients with normal and high serum LDH levels, respectively (P = 0.04). Four-year OS rates were 68.7 percent and 28.5 percent for patients with normal and high serum LDH levels, respectively (P = 0.01). Multivariate analysis also revealed that high serum LDH level was the only independent risk factor that predicted OS. The relative risk was 2.43 (95%CI: 1.08-5.45) for patients with high serum LDH levels (P = 0.03). No independent risk factors associated with DFS were found for other prognosticators. Our study demonstrated that high serum LDH level is the only independent unfavorable risk factor for OS in patients with locoregionally advanced NPC who were treated with NCT plus RT or CCRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661206     DOI: 10.1080/07357900701209103

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  18 in total

1.  Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Authors:  Jian Ji Pan; Wai Tong Ng; Jing Feng Zong; Sarah W M Lee; Horace C W Choi; Lucy L K Chan; Shao Jun Lin; Qiao Juan Guo; Henry C K Sze; Yun Bin Chen; You Ping Xiao; Wai Kuen Kan; Brian O'Sullivan; Wei Xu; Quynh Thu Le; Christine M Glastonbury; A Dimitrios Colevas; Randal S Weber; William Lydiatt; Jatin P Shah; Anne W M Lee
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

2.  Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system.

Authors:  Jeremy Chee; Kwok Seng Loh; Ivan Tham; Francis Ho; Lea Choung Wong; Chee Seng Tan; Boon Cher Goh; Chwee Ming Lim
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

3.  The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma.

Authors:  Xiao-Li Wei; Dong-Sheng Zhang; Ming-Ming He; Ying Jin; De-Shen Wang; Yi-Xin Zhou; Long Bai; Zhe-Zhen Li; Hui-Yan Luo; Feng-Hua Wang; Rui-Hua Xu
Journal:  Tumour Biol       Date:  2015-09-01

4.  Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma.

Authors:  Na Liu; Rui-Xue Cui; Qing-Mei He; Bi-Jun Huang; Ying Sun; Dan Xie; Jing Zeng; Hui-Yun Wang; Jun Ma
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

Review 5.  Cancer's craving for sugar: an opportunity for clinical exploitation.

Authors:  S Yeluri; B Madhok; K R Prasad; P Quirke; D G Jayne
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-05       Impact factor: 4.553

6.  Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area.

Authors:  Zhengbo Wei; Xianjie Zeng; Jian Xu; Xuwei Duan; Ying Xie
Journal:  Onco Targets Ther       Date:  2014-05-15       Impact factor: 4.147

7.  Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy.

Authors:  Chang-Juan Tao; Xu Liu; Ling-Long Tang; Yan-Ping Mao; Lei Chen; Wen-Fei Li; Xiao-Li Yu; Li-Zhi Liu; Rong Zhang; Ai-Hua Lin; Jun Ma; Ying Sun
Journal:  Chin J Cancer       Date:  2013-08-28

8.  Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.

Authors:  Lei Zeng; Pi Guo; Jin-Gao Li; Fei Han; Qiang Li; Yong Lu; Xiao-Wu Deng; Qing-Ying Zhang; Tai-Xiang Lu
Journal:  Oncotarget       Date:  2015-11-17

9.  Prognostic Evaluation of Nasopharyngeal Carcinoma with Bone-Only Metastasis after Therapy.

Authors:  Tianzhu Lu; Qiaojuan Guo; Xiaofei Cui; Zhuhong Chen; Shaojun Lin; Luying Xu; Jin Lin; Jingfeng Zong; Jianji Pan
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

10.  Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.

Authors:  Rujiao Liu; Jun Cao; Xiang Gao; Jian Zhang; Leiping Wang; Biyun Wang; Lin Guo; Xichun Hu; Zhonghua Wang
Journal:  Tumour Biol       Date:  2016-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.